November 18, 2014

# Pressure BioSciences Ships First Two Barozyme HT48 Systems

## Evaluations of PBI's New High-Throughput PCT-based System Underway at a World Renowned Academic/Research Institution and a Leading Biotechnology Company. Additional Evaluations at Key Opinion Leader Laboratories Scheduled.

SOUTH EASTON, Mass., Nov. 18, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced the installation of its first two Barozyme HT-48 high throughput systems for independent evaluation and subsequent potential sale. One system was placed in the laboratory of Dr. Radoslav Goldman of Georgetown University while the other was placed in the laboratory of a leading biotechnology company. In both settings, the Company believes the new systems will deliver important and unique capabilities for the analysis and characterization of biological samples. Both groups are current customers of the Company's patented pressure cycling technology ("PCT")-based products.

The Barozyme HT48 is a first-in-class, high throughput, PCT-based instrument. It is capable of processing up to 48 samples simultaneously using the Company's proprietary BaroFlex 8-well, single-use processing strips. Together, the new Barozyme HT48 instrument and BaroFlex 8-well processing strips make up the Barozyme HT48 High Throughput System (the "Barozyme HT48 System").

The Barozyme HT48 System was designed for rapid, high quality protein digestion - a universally important procedure that the Company believes is conducted in thousands of laboratories worldwide.  The ability of the Barozyme HT48 System to process up to 48 samples simultaneously in the universally accepted "microplate" format is a major improvement in the throughput of sample handling and a key step towards automation of PCT-based sample preparation. The new BaroFlex format of disposable sample containers in 8-well strips lowers the total cost per sample processed by PCT and facilitates integration of PCT processing with robotic automation, essential to the throughput and efficiency of modern laboratories. Lastly, the Barozyme HT48 Systems' computer control was designed to meet GLP compliance demands of biopharmaceutical quality control and clinical proteomics labs.

Dr. Radoslav Goldman, Professor in the Department of Oncology at Georgetown University, and an expert in the detection of liver disease and its progression to cancer, said: "Glycosylated proteins may facilitate the escape of cancer cells from the immune system's surveillance and subsequently help with tumor metastasis. It is therefore crucial that innovative technologies that can potentially enhance the detection of cancer-related molecules – such as certain glycosylated proteins - continue to be developed.  We believe the new Barozyme HT48 System, with the potential to offer accelerated, higher quality

sample preparation, may bring measurable benefits to biomarker discovery for cancer and other diseases."

Dr. Goldman continued: "In addition, glycosylation of protein pharmaceuticals has been shown to increase drug half-life in circulation and thus improve the efficacy of therapeutic compounds. Our laboratory routinely uses PCT-based sample preparation prior to mass spectrometric analysis of glycosylated proteins. We are excited to evaluate PBI's new high throughput, automation-friendly Barozyme HT48 System, as it may allow analyses that are faster, less expensive, and of higher quality than other sample preparation methods now available."

Dr. Nate Lawrence, Vice President of Marketing and Sales at PBI, said: "We are delighted to have the first two independent evaluations of the Barozyme HT48 System being conducted by such well-regarded, important groups. We expect to complete the assembly, release, and shipment of the next three Barozyme HT48 Systems within the coming weeks and to install them shortly thereafter. Many groups have asked or agreed to be included in the Barozyme HT48 System evaluation program, including world renowned pharmaceutical, biotechnology, academic, government, and commercial testing laboratories. We believe these evaluations will fuel growth, increase revenue for existing and new PCT-based applications and products, and greatly facilitate the formation of new strategic partnerships."

**About Pressure BioSciences, Inc.**

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

**Earnings Call**

The Company will hold an Earnings Conference Call at 4:30 PM EST on Tuesday, November 18, 2014. To attend this teleconference via telephone: Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International). Verbal Passcode: PBI Third Quarter 2014 Financial Conference Call, ID 13596109. Replay Number (877) 660-6853; (201) 612-7415 (International). Teleconference Replay Available for 90 days.

**Forward Looking Statements**

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are

subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

**Investor Contacts**:
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Nathan P. Lawrence, Vice President, Marketing and Sales (508) 230-1829 (F)

SOURCE Pressure BioSciences, Inc.